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Abstract
Purpose of Review The concept of value-based health care (VBHC) was articulated more than a decade ago. However, its clinical
implementation remains an on-going process and a particularly demanding one for the domain of head and neck cancer (HNC).
These cancers often present with fast growing tumors in functionally and cosmetically sensitive sites and afflict patients with
differing circumstances and comorbidity. Moreover, the various treatment modalities and protocols have different effects on
functional outcomes. Hence, the interpretation of what constitutes VBHC in head and neck oncology remains challenging.
Recent Findings This monograph reviews developments in specific aspects of VBHC for HNC patients, including establishment
of registries and quality indices (such as infrastructure, process, and outcome indicators). It emphasizes the importance of the
multidisciplinary team, “time to treatment intervals,” and adherence to guidelines. The discussion addresses major indicators
including survival, quality of life and functional outcomes, and adverse events. Also, strengths and weaknesses of nomograms,
prognostic and decision models, and variation of care warrant attention.
Summary Health care professionals, together with patients, must properly define quality and relevant outcomes, both for the
individual patient as well as the HNC population. It is essential to capture and organize the relevant data so that they can be
analyzed and the results used to improve both outcomes and value.
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Introduction
Head and neck cancer (HNC) is characterized by often rela-
tively fast growing tumors in anatomically delicate and func-
tionally vulnerable sites. Tumor progression, resection, and
sequelae of non-surgical management may all eventuate in
durable functional decline. Whereas survival has long been
acknowledged as an important outcome of HNC care, quality
of life is increasingly recognized. Pursuit of cure by intensify-
ing treatment is usually associated with increased adverse
events (such acute toxicity and postoperative complications)
as well as long-term morbidity. This may be acceptable when
balanced against the survival benefits or better quality of life.
Therefore, when defining benefits or outcomes of HNC treat-
ment, both oncologic results as well as quality of life are
important.
With increasing costs of care in many Western societies,
sustaining their health care systems creates problems that can-
not be ignored. Thus, recent years have brought an increased
focus on assessing value (i.e., which quality of care and long-
term outcomes can be achieved at given prices). In his 2010
paper on value-based health care (VBHC), Porter observed
that “Achieving high value for patients must become the over-
arching goal of health care delivery, with value defined as the
health outcomes achieved per dollar spent. This goal is what
matters for patients and unites the interests of all actors in the
system” [1]. Therefore, to define value, it is important to de-
fine relevant outcomes (including toxicity/complications) on
one hand and costs (including waste and unnecessary ex-
pense) on the other. VBHC aims to provide outcomes favor-
able to patients at the fairest possible costs. It should keep
health systems sustainable and continually improving. In an
era of “pay for performance,” a pro-active role of the health
care professionals in defining quality is increasingly important
[2].
This review presents a summary of some important aspects
of quality of care in HNC. Because financial costs in health
care are notoriously difficult to measure and much more de-
pendent on particular features of individual systems, the focus
will be indicators of quality and outcome in HNC care, how to
measure them, and how to use them to improve care.
Quality Indicators and Registries
Within healthcare, there is growing recognition of the need for
accurate and germane information to improve quality because
“Rigorous, disciplined measurement and improvement of val-
ue is the best way to drive system progress” [1]. Hence, the
acquisition of data defining the indicators should be incorpo-
rated in quality registries, which should be prospective, com-
prehensive, and comparable. The virtues of measuring the
quality of medical care and, thereby, fostering its continuing
improvement have been recognized for many years [3].
In 2006, Porter and Teisberg’s book, “Redefining Health
Care” on VBHC [4], resulted in the founding of the
International Consortium for Health Outcomes Measurement
( ICHOM) (ht tp : / /www.ichom.org/ ) . ICHOM has
subsequently developed minimally acceptable data sets for
several diseases, including colorectal, lung, and breast
cancer [5–7]. Other organizations have developed additional
data sets, including for HNC [8•]. To establish the relevant
indicators of quality, suitable indices should ideally be defined
by multidisciplinary groups, using approaches such as the
RAND-modified Delphi method and by engaging all stake-
holders or actors, including patients [8•]. Other means to es-
tablish registries to improve quality of care in daily practice
warrant consideration; quality assurance programs in the con-
text of clinical trials could be elaborated to serve as the basis
for prospective registries as well [9].
Quality registries offer several routes to improve health
care. These include the opportunity to monitor quality of
care delivered and to provide feedback when necessary.
They also make possible auditing to identify differences
in patterns of care, potentially pointing toward improve-
ment. They offer the opportunity to conduct “outcomes
research,” to study “real world” results [10]. In contrast
to clinical trials, which include only subjects meeting de-
fined criteria and interested practitioners or centers, the
unselected population can be analyzed through sufficient-
ly comprehensive registries. However, challenges reside
in the burden of gathering relevant underlying data, cre-
ating the necessary infrastructure, and addressing data
ownership and privacy concerns.
The early adoption, decades ago, of VBHC principles in
Sweden has already resulted in the establishment of more than
100 government-funded registries pursuing the systematic
collection of outcomes, which can be used to guide patient
choice and support learning and quality improvement [11].
The Swedish Head and Neck Cancer Register (SweHNCR),
functional since 2008, is an already well-established HNC
quality registry (http://kvalitetsregister.se/englishpages/
findaregistry/registerarkivenglish/nationalqualityregistry
forheadandneckcancer.2287.html). Additional examples of
how these can provide information to improve quality of
care are emerging in the HNC arena [8, 12, 13]. In low
resource settings similar initiatives may be difficult to
implement but ideas on how to proceed in less developed
settings have been published [14].
Quality indices can include structure, process, and outcome
indicators [15] (Table 1).Which of these are most important is
subject to debate. Optimizing processes of care may be imper-
fect surrogates for improvement rather than truly increasing
the actual quality and value derived by the patient. While
outcomes and costs are the “real” determinants of value,
assessing appropriate process indicators may influence even-
tual outcomes and provide tools to improve them.
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Structure Indicators
Structure indicators reflect the environment of health care de-
livery and provide the basis to provide good care. They consist
of two major factors: personnel and equipment. In addition to
the number of specific caregivers and the diagnostic and ther-
apeutic facilities, the multidisciplinary network (with its de-
gree of centralization) also belongs to the structure indicators.
The medical record and IT support may be considered in this
category as well. Structure indicators may be relatively easy to
define and to measure. However, they alone do not guarantee
quality and may not represent (good) surrogates for something
that the patient actually receives.
The impact of structure might be reflected, for example, in
publications on survival rates of HNC in European countries
[16–18], where clear differences are demonstrated. Although
the reasons for these differences are uncertain, one factor may
be the organization and centralization of care. The Nordic
countries, UK, Ireland, and the Netherlands, with traditions
of decades of centralization and multidisciplinary teams and
clinics, seem to have better survival outcomes [16–18], and
many initiatives are aiming at centralization with the objective
to increase quality and reduce costs [19]. However, demo-
graphics may differ considerably, resulting in difficulties of
comparison between countries.
Centralization is an important feature of structure and
closely related to both volume and experience rate. By cen-
tralization with higher volumes, the experience of the in-
volved health care professionals increases and economies of
scale also permit cost-efficient investments, in (highly) spe-
cialized personnel, infrastructure, and equipment. Analyzing
the impact of centralized care of rare malignancies, including
rare HNCs in Europe [20] confirms the favorable effects of
centralization on survival in rare tumors. Although the bene-
fits of centralization of care of rare diseases are now widely
accepted, they typically reflect a long process. Very strong
scientific evidence is needed to drive physicians to alter their
patterns of care [21].
Volume is sometimes also cited as an outcome measure,
which can be confusing. The differences between low and
high volumes are not well defined, and the definition of vol-
ume is not simple. Systematic review of systematic reviews
establishes a relationship between volume and outcome [22].
However, the definition of minimum required case volumes
remains unanswered for most situations.
Many studies demonstrate a (positive) correlation between
higher volume and better outcomes including those for HNC
[23–31] and salivary gland cancer [32]. One example is the
relation between hospital case volume and outcomes of laryn-
gectomy. Reduced mortality, morbidity, length of hospitaliza-
tion, and costs were associated with higher hospital volume
[24]. Another example in HNC is the recently published as-
sociation between involved surgical margin rates and facility
volume for patients with oropharyngeal carcinoma treated by
transoral robotic surgery [33]. High-volume centers have sig-
nificantly fewer positive surgical margins in oncological sur-
gery than low-volume facilities. However, this easily mea-
sured indicator should be considered a surrogate endpoint.
In addition to the demonstrable advantages of centraliza-
tion, other aspects merit consideration. Patient traveling dis-
tances are increased, potentially reducing adherence, patient
satisfaction, and quality of life [34].
It may be that HNC cases have variable complexity and the
virtues of centralization of oncologic treatment with low com-
plexity should be balanced against the associated costs of
treatment of these cases in tertiary referral centers. However,
even in less complex cases experience is important for optimal
outcomes and appropriate costs. In this regard, organization of
the HNC patient’s pathway into a “hub and spoke” network
model should improve patient satisfaction and quality of care,
as suggested with other cancers [35, 36].
Process Indicators
Process indicators are meant to measure important steps in the
healthcare delivery pathway. The process includes all steps of
the treatment trajectory, from appreciation of the lesion
through diagnostic procedures, treatment, follow-up, and sur-
vivorship. Due to its complexity and impact in cancer care, the
decision-making process is often separately described but still
also as a part of the treatment trajectory.
Multidisciplinary Teams, Integrated Care
One simple process indicator is the presence of a multidisci-
plinary team (MDT).
Table 1 Quality indicators
Structure Process Outcome
Health care professionals’
perspective
Volume, centralization,
registry
MDT, adherence to
guidelines, waiting
times, network
Survival, adverse events
Patients’ perspective Quality of life (PROs),
functional outcome,
experiences (PREs)
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HNC, perhaps more than any other tumor, requires a mul-
tidisciplinary approach. The optimal collaboration and
concertation of all involved disciplines, both medical and al-
lied health professions, is an important basis for quality of care
[37]. The importance of MDTs and their impact on outcomes
is increasingly investigated and recognized [38–41]. Their im-
plementation and optimization have been submitted to study
[39, 42, 43]. MDTs have been associated with improved effi-
ciency and completeness of care [44]. Enthusiasm for adop-
tion of MDTs varies between countries. Some have had them
for decades, and some health systems are still attempting to
establish them.
The exact definition of what should constitute a MDT
varies, but head and neck oncology MDTs are typically com-
posed of the three major disciplines involved in the treatment
of these malignancies: radiation oncology, medical oncology,
and head and neck surgery (including reconstructive surgery).
In addition, specialists such as radiologists, pathologists, ger-
iatricians, dentists, and allied health professionals such as nu-
tritionists, cancer nurses, physiotherapists, oral hygienists, so-
cial workers, and psychologists are key participants.
Typically, these care-givers are mainly involved in the
decision-making process during MDT meetings; however,
specific patient or tumor characteristics regularly necessitate
the involvement of other disciplines.
Establishment of a “MDT” as such does not guarantee
uniformity of decisions, and there are no standardized
methods to conduct MDT meetings. Guideline adherence
may vary, and decisions often vary depending on prefer-
ences of individual professionals attending the MDT; they
may be influenced by factors such as authority, institu-
tional preferences, or school. For optimal functioning of
multidisciplinary teams collegiality or a good “team cli-
mate” is important [45].
Rankin et al. conducted a descriptive study on team func-
tioning, the role of teammeetings, and evidence use inMDTs.
They found that MDT treatment decisions were based on
group consensus (92%), adherence to clinical practice guide-
lines (57%), or other evidence-based medicine sources (33%)
[46]. Kirkegård et al. showed a high heterogeneity in the stag-
ing of pancreatic tumors and in the definition of resectability
between European MDTs [47]. Similar variability is to be
expected between head and neck MDTs.
As suggested by Guy et al., MDTmeetings are necessary at
every stage of disease [43].
Although there are currently no doubts about the benefits
of MDTs, introduction and quality assurance are challenging,
particularly in low-resource settings. Difficulties in establish-
ing an MDT have also been identified: it is time-consuming,
synchronizing physician availability may be challenging, and
sometimes there are concerns that waiting for the MDT meet-
ing will engender treatment delay [48]. In order to answer
these issues, teleconsultation services could help, particularly
for specific questions, such as pathology review or speech
pathology consultation [49].
Adherence to Guidelines
Guidelines form the basis to standardize and optimize deliv-
ered care. They are usually developed according to evidence-
based principles and use the best information available. They
are considered superior to physician experience-based treat-
ment practice. Therefore, adherence to guidelines is consid-
ered a process indicator. However, application of guideline
recommendations to a specific case should be undertaken with
care. Patients in practice often significantly differ from the
population of the trials, which often serve as a basis for the
guideline.
Prospective registries/databases used for quality purposes
may also serve as sources for outcomes research and guide-
lines. In contrast to randomized trials in which the population
is selected by inclusion criteria, data generated by quality or
disease registries offer the opportunity to study outcomes in
clinical reality and may form the basis for guideline develop-
ment and maintenance.
The development and maintenance of head and neck on-
cology guidelines should, of course, be multidisciplinary, but
the involvement of patients in the development of guidelines
and in research is increasingly acknowledged as important and
valuable [50–52]. However, it is likely to be difficult to dem-
onstrate that their inclusion is associated with improved out-
comes [53].
Although the quantity and quality of information provided
by guidelines is accumulating, actual adherence to recommen-
dations involves barriers [54] and keeping the guidelines up to
date is challenging. An example is the adherence to thyroid
cancer management guidelines and application of the guide-
line of timely inception of postoperative radiation therapy,
which has room for improvement [55, 56].
Time to Treatment Initiation
Another prominent process indicator is the time to treatment
initiation.
As HNC is often relatively fast growing in an anatomically
complex and functionally vulnerable site, it is conceivable that
any tumor progressions would affect survival and/or quality of
life.
The detrimental effect of prolonged time to treatment initi-
ation intervals on outcome is difficult to study but both onco-
logical outcomes (survival) and/or functional (quality of life)
and psychological (e.g., anxiety) disadvantages are to be ex-
pected [57•, 58–60]. Conversely, outcome is influenced by
many factors and it is difficult to demonstrate the effect of
one single factor. Anyway, tumor progression may necessitate
intensified treatment, compensating the potential loss of
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survival but increasing toxicity and costs (which are not often
measured but are important in the equation of value of care).
Due to the complexity of HNC care, often requiring multi-
ple imaging techniques, sometimes diagnostic endoscopy un-
der general anesthesia, and often involving patients with mul-
tiple medical problems/comorbidities, timely start of treatment
can be challenging but is to be desired [61]. An increase in
time to treatment initiation in the USA is reported In recent
publications, including its effect on survival [57•, 62, 63]. In
Denmark this topic has been studied and a similar trend re-
ported. The findings resulted in nation-wide initiatives to ex-
pedite the diagnostic maneuvers and initiation of treatment
[64, 65•]. Similar guidelines or targets have been defined in
other countries as well. In 2005, the UK National Institute for
Health and Care Excellence (NICE) first published clinical
guidelines for the recognition and referral of suspected cancer.
Updated in 2015, the Department of Health currently has
specified times within which patients with suspected cancer
should be seen; the national target is 14 days from the day of
referral from primary care [66, 67].
Networks
Another relevant aspect may be the organization of care in a
network for communication and collaboration between sec-
ondary and tertiary referral centers [68]. Timely referral and
execution of diagnostic procedures may reduce time to treat-
ment initiation and therefore enhance outcomes. Doing the
proper diagnostic procedures according to the correct proto-
cols and guidelines in dedicated head and neck centers (elim-
inating need to repeat them) and avoiding unnecessary proce-
dures adds to cost-effectiveness and timely treatment.
Communication and sharing of imaging are facilitated by the
possibilities of modern technology such as teleconferencing to
organize consultation. Larger networks of head and neck on-
cologic care can pursue clinical research to increase knowl-
edge of rare diseases [69].
Outcome Indicators
A broad spectrum of both objective and subjective measures
comprise outcome indicators. Traditionally, survival has been
considered the most important outcome indicator in cancer
care, but it is now recognized that adverse events and quality
of life are also important. Prioritizing these outcomes may
significantly differ between patients, their caregivers, and
members of care teams [70••].
Quality of life measured by patient reported outcomes
(PROs) and experiences (PREs) is subjective by nature. This
concerns both disease-specific and generic health-related
quality of life measures. The comparison of these indicators
between different patient cohorts is difficult because outcome
measures are dependent on external factors. Priorities may
change. For instance, elderly HNC patients favoring quality
of life to prolonged life [71, 72]. Hence, the introduction of
geriatric screening may lead to shorter survival; however, pa-
tient satisfaction (expressed in PREs and PROs) may increase
[73].
Survival
As mentioned above, survival has been regarded traditionally
the most important outcome parameter. Survival rates have
been improved through the years (https://seer.cancer.gov/csr/
1975_2016/browse_csr.php?sectionSEL=2&pageSEL=sect_
02_table.08). However, it is uncertain to which extent
progress in both the surgical (e.g., robotic surgery) and non-
surgical treatment modalities (e.g., proton therapy and immu-
notherapy) during the past decade have added to survival
benefit.
Introduction of new treatment options or paradigms as such
is not always accompanied by better survival but may instead
be primarily driven by less associated toxicity or morbidity of
a treatment in combination with unaltered survival. An exam-
ple is the introduction of organ preservation treatment regi-
mens [74, 75].
Quality of Life and Functional Outcomes
Quality of life and of supportive care have been increasingly
recognized critical to delivering optimal results [76, 77•].
They are closely related to functional outcomes of treatment
such as speech articulation, swallowing, taste, jaw opening,
and saliva production in head and neck oncology. However,
there are many important domains for head and neck cancer
patients, and assessing the impact of treatment is demanding
[78].
The prospective collection of these data provides important
information on “real life” care but is challenging for both
PROs and functional outcomes [79••, 80]. The acquisition of
PROs through questionnaires requires motivating patients to
complete them. Even in the context of clinical trials, the com-
pliance of patients in providing the information may be poor
unless the individual results are also actually used in practice
[81]. Nonetheless, for (shared) decision making and weighing
oncological outcomes against quality of life outcomes, the
measurement and knowledge of quality of life issues are es-
sential [82–86].
Patient Experiences
Another parameter reflecting quality of care is how patients
experience its delivery. It is important to know the needs and
preferences of patients and assess their perceptions and expe-
riences [87, 88]. There are several methods to measure these
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preferences and experiences including interviews and the use
of patient-reported experience (PRE) questionnaires.
Adverse Events (Complications and Toxicity)
Adverse event (AE) is a term including harmful events such as
postoperative complications and toxicity. AEs have always
been a part of health care. However, their corresponding sys-
tematic measurement has a short history. The US National
Cancer Institute has developed a system (Common
Terminology Criteria for Adverse Events—CTCAE) to allow
health-care providers to score and to compare AEs.
Treatment-related AEs form the 14th most common cause of
disease burden worldwide with significant financial conse-
quences [89]. The most common reported AEs are health-
care-associated infections (or hospital-acquired infections)
[90]. In head and neck oncology, treatment-related AEs are
well-defined and sophisticated efforts and strategies have been
developed to limit them. Radiation-induced toxicity signifi-
cantly affects patients’ short- and long-term quality of life.
Operations also engender unwanted sequelae and complica-
tions with related mortality and morbidity. Prediction models
have been developed, which may help in the decision-making
process and in choosing the best treatment [91]. Quality as-
surance in head and neck surgery suggests structured registries
including those of surgical complications and their risk factors
[92]. In specific patient populations (e.g., elderly or infirm)
adverse events have other predictors, other consequences, and
sequelae [93]; it is uncertain how these should influence ther-
apeutic decision making [94].
In patients with recurrent and/or metastatic disease, the
application of systemic treatments in the last month of life
should be considered another care quality indicator.
Treatment in these patients may cause a high adverse event
burden and a consequent deterioration in already poor quality
of life. For this reason, there is a general recommendation not
to administer chemotherapy near the end of life [95].
Nomograms, Prognostic Models, and Decision
Models
“Big data” may provide valuable information and form the
basis for nomograms and decision models that are receiving
growing attention in health care. These tools may allow pre-
diction of “individual” outcomes, which contributes to both
physician and patient decision making and perhaps also to
better outcomes. Prediction models have been significantly
improved in the last decades with setting up large databases
and with the development of analytical tools and methods.
Using “big data,” prediction models became more reliable.
Examples of prognostic models combining patient character-
istics, such as age, sex, and comorbidities and also tumor
factors, primary site, and TNM classification have been pub-
lished [96] including their validation on other populations
[97]. However, the issues of application to different popula-
tions have not been entirely resolved [98].
Models for specific patient categories [99] or clinical ques-
tions (e.g., elective neck treatment, post-operative radiation)
have been published [100]. These may eventually be integrat-
ed into the decision-making process in order to enhance sur-
vival, quality of life, adverse event outcomes, and reduce
health care costs [101].
Learning from Variation
Even within the context of clinical trials and even between
comparable centers, outcomes may vary. Variation in adher-
ence to guidelines and quality of delivered care has been doc-
umented within the context of randomized trials in which
quality assurance is included and also in studies using data
from population/cancer registries [31, 102, 103, 104••].
Analysis of these findings may lead to improved quality and
outcomes by identifying best practices and learning from
them. Translating these analyses to recommendations and
guidelines should favorably influence outcome results in clin-
ical practice [105, 106].
Final Remarks and Considerations
In this paper focus has been put on quality of care but, with
increasing costs of health care in particular, the question of
costs is relevant as well. However, as already stated in the
introduction, financial costs in health care are notoriously dif-
ficult to measure and much more dependent on particular fea-
tures of individual systems. As, in the concept of VBHC,
value is defined as outcomes relative to costs, there is also
risk: focusing on cost reduction to increase “value.” As
Porter stated, “cost reduction without regard to the outcomes
achieved is dangerous and self-defeating, leading to false
“savings” and potentially limiting effective care” [1].
Therefore, it is crucial for health care professionals together
with their patients to properly define quality and relevant
outcomes.
Clearly, there are many ways to define and improve the
quality of delivered care and to create value for patients re-
quires knowing what really matters to them (their needs and
preferences). Moreover, the creation of value is a multifaceted
and much more than “What do I get for this price?” How,
where, when, and by whom is value created? It may be worth-
while to look for parallels in other sectors. Heinonen et al.
have assessed the multi-dimensional aspects of value creation
in the online-commercial world by unraveling it into matrices.
They found that firms tend to miss values because they focus
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on their own resources and capabilities, rather than expanding
their scope (https://hbr.org/product/strategies-for-creating-
value-through-individual-and-collective-customer-
experiences/BH956?sku=BH956-PDF-ENG). Does this
translate into health care and if so, how?
Next to defining quality and outcomes reflecting this, it is
essential to collect the relevant “real world” data. Only this
will allow both analysis of the contributing factors and poten-
tial novel parameters to improve patient outcomes.
Establishing quality registries is a way to acquire data show-
ing where quality improvements can be achieved and optimiz-
ing the balance between outcomes and costs. Emerging “big
data” from these registries can also be used to develop tools to
help to provide individualized and tailored treatments, thus
improving individual patient outcomes and adding to the over-
all improvement of outcomes for the entire population. To be
useful and feasible, these registries should be prospective,
comprehensive, and comparable and registration burden
should be minimized. Moreover, a system is needed to trans-
late these outcomes into actions to actually improve, to remea-
sure, and in such a way to create a quality cycle.
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